Elicera Therapeutics AB Cash Flow Quality Index

Latest as of September 2025: -15.58x

Elicera Therapeutics AB cash flow quality index. Elicera Therapeutics AB (ELIC) has a Cash Flow Quality Index of -15.58x as of September 2025. Operating cash flow of Skr-4.74 Million is below net income of Skr304.15K, suggesting accrual-heavy earnings not yet converted to cash. See Elicera Therapeutics AB (ELIC) flexibility index to measure the company's free cash flow as a share of total liabilities.

Cash Flow Quality Index

-15.58x

Operating CF / Net Income

Operating Cash Flow

Skr-4.74 Million

SEK

Net Income

Skr304.15K

SEK

Data as of

Sep 2025

Most recent filing

Elicera Therapeutics AB Cash Flow Quality Index by Year (None–None)

Elicera Therapeutics AB cash flow quality index by year from None to None. Year-by-year earnings quality comparison for Elicera Therapeutics AB. For the full cash flow conversion analysis, see ELIC operating cash flow.

Year	Quality Index	Operating CF (SEK)	Net Income	YoY Change

Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.